Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (8927)	3/4/1999 11:03:00 AM
From: Bluegreen	Respond to of 17367

Opal, I thought things were spelled out very clearly in FAQ provided from Xoma, that is why I said you were hitting below the belt. Shame on you Opal, you have read this stuff before. From FAQ that is available on XOMA WEBSITE.>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Are you holding out too long to get a NEUPREX® deal on the table? (7/98) We believe NEUPREX® has large sales potential in multiple indications. Therefore, we have set a substantial entry price for the product and want a major product commitment from a partner to pursue our multi-indication strategy. We are already in two Phase III trials, and good trial results could only improve the value of the product. Furthermore, our first approvals could well be for small indications, like meningococcemia or cystic fibrosis, which do not require a large pharma company sales force. Therefore, while we still look forward to doing the right deal with the right partner, at this stage we can afford to wait.<<<<<<<<<<<<<<<<